Skip to main content

Table 3 Risk of death or disease recurrence associated with CHEK2:p.I157T

From: Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium

(a) All breast cancer patients Univariate analysis Adjusted analysis
I157T/nc I157T/1100delC 1100delc/nc I157T/nc I157T/1100delC 1100delC/nc
Early death 0.85 [0.68 - 1.07] 0.74 [0.50 - 1.09] 1.28 [1.00 - 1.64] 0.80 [0.60 - 1.07] 0.51 [0.29 - 0.90] 1.32 [0.94 - 1.86]
0.16 0.12 0.054 0.13 0.0190 0.11
Breast cancer-specific death 0.85 [0.60 - 1.20] 0.64 [0.37 - 1.12] 1.44 [1.04 - 2.00] 0.93 [0.62 - 1.40] 0.46 [0.21 - 1.03] 1.25 [0.78 - 2.00]
0.36 0.12 0.030 0.73 0.058 0.36
Distant metastasis relapse 1.04 [0.79 - 1.37] 0.66 [0.38 - 1.14] 1.38 [0.90 - 2.11] 1.05 [0.75 - 1.47] 0.62 [0.31 - 1.23] 1.37 [0.83 - 2.26]
0.79 0.13 0.14 0.76 0.17 0.22
Locoregional relapse 1.43 [0.92 - 2.23] 0.81 [0.58 - 1.13] 2.07 [1.16 - 3.69] 1.62 [0.99 - 2.66] 0.91 [0.33 - 2.52] 1.26 [0.59 - 2.70]
0.11 0.21 0.014 0.056 0.85 0.55
Second breast cancer 1.54 [0.85 - 2.78] 0.69 [0.47 - 1.03] 2.88 [1.68 - 4.98] 2.03 [1.05 - 3.92] 0.69 [0.42 - 1.13] 3.62 [1.82 - 7.21]
0.15 0.070 0.00015 0.035 0.14 0.00026
(b) Patients with ER+ breast cancer Univariate analysis Adjusted analysis
I157T/nc I157T/1100delC 1100delc/nc I157T/nc I157T/1100delC 1100delC/nc
Early death 0.81 [0.61 - 1.07] 0.62 [0.39 - 0.99] 1.32 [0.98 - 1.78] 0.77 [0.55 - 1.07] 0.46 [0.25 - 0.85] 1.52 [1.06 - 2.17]
0.14 0.044 0.067 0.12 0.013 0.022
Breast cancer-specific death 0.80 [0.51 - 1.23] 0.47 [0.23 - 0.96] 1.46 [0.96 - 2.22] 0.80 [0.49 - 1.32] 0.33 [0.13 - 0.84] 1.50 [0.92 - 2.45]
0.30 0.038 0.074 0.39 0.019 0.10
Distant metastasis relapse 1.00 [0.71 - 1.40] 0.55 [0.29 - 1.02] 1.58 [0.99 - 2.54] 1.03 [0.70 - 1.51] 0.56 [0.26 -1.19] 1.61 [0.94 - 2.77]
0.98 0.057 0.056 0.88 0.13 0.083
Locoregional relapse 1.46 [0.86 - 2.47] 0.77 [0.52 - 1.14] 2.33 [1.19 - 4.57] 1.58 [0.90 - 2.79] 0.93 [0.29 - 2.98] 1.08 [0.44 - 2.66]
0.16 0.19 0.014 0.11 0.90 0.87
Second breast cancer 1.33 [0.64 - 2.75] 0.58 [0.37 - 0.92] 4.09 [2.31 - 7.26] 1.81 [0.82 - 3.96] 0.61 [0.36 - 1.04] 4.39 [2.17 - 8.87]
0.44 0.019 1.4E-06 0.14 0.067 3.8E-05
(c) Patients with lobular breast cancer Univariate analysis  
I157T/nc
Early death 0.67 [0.39 - 1.15]
0.14
Breast cancer-specific death 0.91 [0.46 - 1.80]
0.79
Distant metastasis relapse 0.87 [0.48 - 1.57]
0.64
Locoregional relapse 2.45 [0.95 - 6.34]
0.065
Second breast cancer 1.92 [0.57 - 6.49]
0.29
  1. Hazard ratios with 95 % confidence intervals (in parenthesis) and p values (italics) are reported from comparisons of p.I157T carriers and non-carriers (nc) as well as comparisons of p.I157T carriers and c.1100delC carriers. All analyses were stratified by study. Multivariate analyses were stratified by study and age category, and adjusted for tumor grade, size, progesterone receptor and nodal status. Analyses were performed also in subgroups of (b) patients with estrogen receptor-positive tumors and (c) patients with lobular tumors
  2. ER estrogen receptor